Literature DB >> 8061108

Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding.

F Gieseler, H Biersack, T Brieden, J Manderscheid, V Nüssler.   

Abstract

In order to interact with topoisomerase II and induce genotoxicity, anthracyclines have to cross the outer cell membrane and the cytoplasm, enter the nucleus, and bind to the DNA. We incubated sensitive and resistant hematopoietic cells from cell lines and patient cells with daunorubicin, idarubicin, and its active derivative idarubicinol, extracted the anthracyclines from whole cells and nuclei, and determined their concentration fluorimetrically. Additionally, the DNA binding of the drugs was evaluated in the same cells by determining fluorescence resonance energy transfer between the anthracyclines and DNA-bound Hoechst dye 33342. We found a several thousand-fold accumulation of anthracyclines in sensitive and resistant hematopoietic cells; 30-60% of the drugs are found in the nucleus, resulting in 200- to 300-fold differences in concentration between the nucleus and outer fluids. A small proportion of the intracellular or intranuclear anthracyclines is bound to the DNA. The amount of DNA-bound anthracyclines correlates directly to cell death. It takes an additional 10 min for idarubicin and 30 min for daunorubicin to satisfy DNA binding sites after the drugs have arrived in the nucleus. The described methods provide the means to perform ex vivo studies on clinical material.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8061108     DOI: 10.1007/bf01757349

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  15 in total

1.  Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells.

Authors:  E C Spoelstra; H V Westerhoff; H Dekker; J Lankelma
Journal:  Eur J Biochem       Date:  1992-07-15

2.  Can cytotoxic activity of anthracyclines be related to DNA damage?

Authors:  M Nishiyama; N Horichi; Z Mazouzi; M Bungo; N Saijo; H Tapiero
Journal:  Anticancer Drug Des       Date:  1990-02

3.  Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.

Authors:  M J Kuffel; J M Reid; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions.

Authors:  R Pieters; A H Loonen; D R Huismans; G J Broekema; M W Dirven; M W Heyenbrok; K Hählen; A J Veerman
Journal:  Blood       Date:  1990-12-01       Impact factor: 22.113

5.  DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin.

Authors:  E Ferrazzi; J M Woynarowski; A Arakali; D E Brenner; T A Beerman
Journal:  Cancer Commun       Date:  1991-06

6.  HPLC and flow cytometric analyses of uptake of adriamycin and menogaril by monolayers and multicell spheroids.

Authors:  T J Bichay; E G Adams; W R Inch; W J Adams; J E Brewer; B K Bhuyan
Journal:  Sel Cancer Ther       Date:  1990

7.  In vivo and in vitro pharmacokinetic differences between four structurally closely related anthracyclines in hematopoietic cell subtypes in humans.

Authors:  P A Speth; P C Linssen; E F Termond; J B Boezeman; H M Wessels; C Haanen
Journal:  Drug Metab Dispos       Date:  1989 Jan-Feb       Impact factor: 3.922

8.  Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo).

Authors:  G Belvedere; A Suarato; C Geroni; F C Giuliani; M D'Incalci
Journal:  Biochem Pharmacol       Date:  1989-11-01       Impact factor: 5.858

9.  Intercalation of anthracyclines into living cell DNA analyzed by flow cytometry.

Authors:  F Belloc; F Lacombe; P Dumain; F Lopez; P Bernard; M R Boisseau; J Reifers
Journal:  Cytometry       Date:  1992

Review 10.  DNA topoisomerase II as the primary target of anti-tumor anthracyclines.

Authors:  F Zunino; G Capranico
Journal:  Anticancer Drug Des       Date:  1990-11
View more
  5 in total

Review 1.  Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer.

Authors:  M M Buckley; H M Lamb
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

2.  Effect of the cytostatic agent idarubicin on fibroblasts of the human Tenon's capsule compared with mitomycin C.

Authors:  C Heilmann; P Schönfeld; T Schlüter; R Bohnensack; W Behrens-Baumann
Journal:  Br J Ophthalmol       Date:  1999-08       Impact factor: 4.638

3.  Simultaneous delivery of chemotherapeutic and thermal-optical agents to cancer cells by a polymeric (PLGA) nanocarrier: an in vitro study.

Authors:  Yuan Tang; Tingjun Lei; Romila Manchanda; Abhignyan Nagesetti; Alicia Fernandez-Fernandez; Supriya Srinivasan; Anthony J McGoron
Journal:  Pharm Res       Date:  2010-08-06       Impact factor: 4.200

4.  Thermal and pH Sensitive Multifunctional Polymer Nanoparticles for Cancer Imaging and Therapy.

Authors:  Tingjun Lei; Romila Manchanda; Alicia Fernandez-Fernandez; Yen-Chih Huang; Douglas Wright; Anthony J McGoron
Journal:  RSC Adv       Date:  2014-01-01       Impact factor: 3.361

5.  Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs.

Authors:  K Nagasawa; N Ohnishi; T Yokoyama
Journal:  Jpn J Cancer Res       Date:  1997-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.